DOR BioPharma Announces FDA Clearance to Conduct Phase 2 Clinical Trial of orBec(R) for the Prevention of GVHD (RedNova)
DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced that it has received clearance from the U.S. Food and Drug Administration ("FDA") to conduct a Phase 2 clinical trial of orBec(R) for the prevention of Graft-versus-Host disease ("GVHD").

Abbott's Hot Streak Includes News On Crohn's (Investor's Business Daily via Yahoo! News)
The good news keeps coming in bunches for Abbott Laboratories.

DOV Pharmaceutical, Inc. Announces Fourth Quarter and 2006 Year-End Results (PR Newswire via Yahoo! Finance)
DOV Pharmaceutical, Inc. announced today results for the fourth quarter and year ended December 31, 2006.